Stock Updates

Morning Trending Tickers: Regeneron Pharmaceuticals, Inc., (REGN)

Friday February 24th 2017: Regeneron Pharmaceuticals, Inc., REGN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Regeneron Pharmaceuticals, Inc., REGN  has a market cap of 53.68 B. Since its IPO date on the 04/02/1991, Regeneron Pharmaceuticals, Inc., REGN performance year to date is 37.54%. Today Regeneron Pharmaceuticals, Inc., REGN has gained -0.03%, with a current price of 504.9.

Ownership of the company is 1.00% for insider ownership while institutional ownership is 71.30%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 13.80%, with return on investment at 18.20%.

In terms of debt levels and profit levels, Regeneron Pharmaceuticals, Inc., REGN is seeing a long-term debt/equity of 0.14. While Total debt/equity is 0.15. With a profit margin of 19.30%, this is combined with a gross margin of 94.50%, and operating margin of 28.80%. Regeneron Pharmaceuticals, Inc. ability to meet debt levels, with a current ratio of 2.8, while the quick ratio is 2.6.

For the last year Regeneron Pharmaceuticals, Inc., REGN has seen a EPS growth of 39.50%. A performance for the year of 38.23%. The 52-week high is -7.11%, and the 52-week low is 55.19%. The average volume for Regeneron Pharmaceuticals, Inc., REGN is 608260.

With a target price of 473.45, can Regeneron Pharmaceuticals, Inc., REGN reach this target? Looking at the value indicators of Regeneron Pharmaceuticals, Inc., REGN. Regeneron Pharmaceuticals, Inc. has a P/E of 60.74 and a forward P/E of 33.28. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.2. Regeneron Pharmaceuticals, Inc. also has a P/S and a P/B of 10.78 and 10.95 respectively. For P/cash, Regeneron Pharmaceuticals, Inc. has a value of 41.07, while it is 38.32 for P/free cash flow.

At the current price of 504.9, Regeneron Pharmaceuticals, Inc. has a dividend yield of *TBA. We see a return on equity of 21.50%.

Looking more long-term Regeneron Pharmaceuticals, Inc., is projected to get an EPS growth for the next five years of 19.01%. In the short-term an EPS growth of 19.19% in the next year is forecasted. This is after a EPS growth of 39.50% for this year and for the last five years a 38.80% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment